HILS NASDAQ
Bridgewater, NJ 08807
US
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| MILBY RANDY | P-Purchase | 29,000 | $0.50 | 2023-12-15 |
| MILBY RANDY | P-Purchase | 10,000 | $1.00 | 2023-11-30 |
| Bui Lynne A. | A-Award | 25,000 | $0.16 | 2023-11-07 |
| Appajosyula Sireesh | A-Award | 25,000 | $0.16 | 2023-11-07 |
| Anderson Kelly | A-Award | 50,000 | $0.16 | 2023-11-07 |